LL-37

An antimicrobial peptide that boosts the immune system’s ability to fight bacterial and viral infections while promoting wound healing.

LL-37

LL-37

An antimicrobial peptide that boosts the immune system’s ability to fight bacterial and viral infections while promoting wound healing.

  • Starting at $399
Order LL-37

What Is LL-37?

LL-37 is a naturally occurring antimicrobial peptide derived from the human cathelicidin protein. It plays a critical role in innate immunity by helping the body defend against bacterial, viral, and fungal pathogens. Beyond antimicrobial activity, LL-37 has been studied for its ability to modulate immune responses, support tissue repair, and enhance wound healing.

  • Promotes tissue regeneration and wound healing.
  • Demonstrates antimicrobial activity against bacteria and viruses in research models.
  • Modulates inflammatory signaling pathways.

Who Can Benefit from LL-37?

LL-37 may be considered in clinical strategies where immune resilience and infection defense are priorities. Individuals with recurrent or persistent infections. Those recovering from complex wounds or slow tissue healing. Patients requiring immune support during high-risk exposure periods. Individuals addressing biofilm-related or resistant microbial patterns (under medical supervision).

  • Promotes wound healing and tissue regeneration
  • May help disrupt microbial biofilms in research settings
  • Supports balanced inflammatory response

OUR CLIENTS LOVE US - SEE WHAT THEY'RE SAYING

Frequently Asked Questions –
Your Concierge Healthcare, Simplified

LL-37 is part of the body’s natural first-line immune defense. It helps directly disrupt microbial membranes and also signals immune cells to respond more effectively to infection.

No. It is not a traditional antibiotic. It is a host-defense peptide that supports the body’s innate immune response.

Protocols vary. Because it actively stimulates immune pathways, it is typically used strategically and under medical supervision.

Research suggests LL-37 may have activity against microbial biofilms, which are protective structures formed by certain bacteria. Clinical application should be guided by a provider.